Oxymatrine suppresses oral squamous cell carcinoma progression by suppressing CXC chemokine receptor 4 in an m6A

Renhui Luo1, Lili Xie2, Yingmei Lin1

  • 1Department of Stomatology, Guangzhou Hospital of Integrated Traditional and West Medicine, Guangzhou, Guangdong 510800, P.R. China.

Oncology Reports
|August 25, 2022
PubMed

Insights

Oxymatrine demonstrates antitumor effects against oral squamous cell carcinoma (OSCC). It inhibits cancer progression by reducing METTL3, degrading CXCR4 mRNA, and decreasing m6A modification, ultimately suppressing tumor growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Oral squamous cell carcinoma (OSCC) is a significant global health concern.
  • Oxymatrine, a natural compound, exhibits potential antitumor properties, but its specific role in OSCC requires elucidation.

Purpose of the Study:

  • To investigate the antitumor effects of oxymatrine in OSCC.
  • To explore the underlying molecular mechanisms, focusing on the regulation of CXC chemokine receptor 4 (CXCR4) and its associated modifications.

Main Methods:

  • Cell Counting Kit-8, apoptosis, and Transwell assays were used to assess antineoplastic effects in vitro.
  • In vivo tumor growth inhibition was evaluated.
  • Western blotting, RT-qPCR, RNA stability, and methylated RNA immunoprecipitation assays were employed to analyze CXCR4 regulation and m6A modification.

Main Results:

  • Oxymatrine significantly inhibited OSCC cell proliferation and migration while promoting apoptosis.
  • Oxymatrine reduced both CXCR4 mRNA and protein levels by enhancing mRNA degradation.
  • The compound decreased m6A modification of CXCR4 mRNA by downregulating methyltransferase-like 3 (METTL3) expression, leading to reduced tumor growth in vivo.

Conclusions:

  • Oxymatrine exhibits significant antitumor activity against OSCC.
  • The mechanism involves the downregulation of METTL3, leading to decreased m6A modification of CXCR4 mRNA, subsequent degradation, and inhibition of OSCC progression and tumor growth.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
548
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K